SAN DIEGO--(BUSINESS WIRE)--Ambit Biosciences today announced significant enhancements to its KinomeScan™ profiling technology, the industry’s most comprehensive high-throughput system for screening small molecule libraries against large numbers of human kinases. Ambit has added 36 new kinases to its screening panel, including therapeutically relevant lipid, mutant, and atypical kinases. Ambit’s customers now can choose from a total of 353 human kinases to power their drug discovery and optimization efforts.
